GlassScriptPhysician profile
Jill Ann Overman
NPI 1063056372
$4,385.51
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,306 · 2022: $1,063 · 2023: $1,876 · 2024: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,016.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $620.10 | 2021-2023 | |
| Axsome Therapeutics, INC. | $543.29 | 2023-2024 | Sunosi, Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $402.17 | 2021-2023 | |
| Lundbeck LLC | $337.66 | 2021-2023 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $317.22 | 2021-2023 | Rexulti, Abilify Mycite |
| Janssen Pharmaceuticals, INC | $305.90 | 2022-2023 | Spravato |
| Bausch Health US, LLC | $231.99 | 2021-2023 | Aplenzin |
| Teva Pharmaceuticals USA, INC. | $191.93 | 2023 | Austedo Xr, Uzedy, Austedo |
| Tris Pharma INC | $183.48 | 2022-2023 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $179.19 | 2021-2023 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $166.72 | 2021-2023 | Trintellix |
| Sunovion Pharmaceuticals INC. | $166.54 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $156.91 | 2022-2023 | Jornay Pm |
| Alkermes, INC. | $142.67 | 2021-2023 | Aristada, Lybalvi |
| Eisai INC. | $142.19 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $58.87 | 2022-2023 | Qelbree |
| Noven Therapeutics, LLC | $56.61 | 2023 | Xelstrym |
| Idorsia Pharmaceuticals US INC | $44.79 | 2022-2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $42.60 | 2021-2022 | |
| Corium, LLC | $41.74 | 2023 | Azstarys |
| Adlon Therapeutics L.P. | $20.23 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.73 | 2024 | Cobenfy |
| Neos Therapeutics, LP | $14.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Overman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.